XMP Biomarker Prediction for Myelodysplastic Syndrome Dosing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for evaluating the effectiveness of 5-hydroxy-1H-imidazole-4-carboxamide in myelodysplastic syndrome patients are cumbersome, time-consuming, and do not accurately reflect in vivo IMPDH inhibition, making it difficult to predict an effective dose and patient sensitivity due to challenges in analyzing trace amounts of xanthosine monophosphate (XMP) in blood.
Innovation Solution
A method involving mass spectrometry to determine XMP levels in blood before and after administration of 5-hydroxy-1H-imidazole-4-carboxamide, calculating the ionic strength ratio, and using specific chromatography conditions to quantify XMP, allowing for the prediction of an effective dose and patient sensitivity in a simple and timely manner.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional methods (PBMC fractionation and in vitro IMPDH inhibition evaluation) are used to assess treatment effectiveness, then IMPDH inhibition can be evaluated, but the process becomes cumbersome and time-consuming
Solution Approach 1:
The invention extracts and measures XMP directly from whole blood samples without requiring PBMC fractionation. By focusing on the specific biomarker (XMP) that reflects IMPDH inhibition in vivo, the method eliminates the time-consuming cell separation step while maintaining evaluation accuracy
Solution Approach 2:
The invention uses XMP as an intermediary biomarker to indirectly evaluate IMPDH inhibition. Instead of directly measuring enzyme activity in vitro, the method measures the downstream metabolite XMP in whole blood, which serves as a reliable proxy for IMPDH inhibition effectiveness
2Reliability
If conventional methods are used to evaluate treatment effects, then IMPDH inhibition can be assessed, but it takes too much time and cannot reflect in vivo conditions accurately
Solution Approach 1:
XMP serves as an intermediary biomarker that reflects in vivo IMPDH inhibition status. By measuring XMP levels in whole blood, the method captures the actual physiological effect of the drug in the patient's body without requiring in vitro cell culture
Solution Approach 2:
The method extracts and measures XMP directly from whole blood samples, eliminating the need for time-consuming PBMC isolation and in vitro incubation steps. This direct measurement approach maintains reliability while dramatically reducing evaluation time
3Measurement precision
If trace amounts of XMP in blood are analyzed using conventional methods, then XMP levels can be determined, but the analysis becomes complex and time-consuming
Solution Approach 1:
The invention uses stable isotope-labeled XMP as an internal standard and intermediary reference to accurately quantify trace XMP levels. This approach simplifies the analysis by providing a reliable reference point for mass spectrometry measurement
Solution Approach 2:
The method replaces complex chromatographic separation and purification procedures with direct mass spectrometry measurement of XMP in whole blood. By using targeted mass spectrometry with isotope labeling, the invention eliminates multiple manual processing steps while maintaining high measurement precision
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables accurate and rapid determination of XMP levels in blood, allowing for the prediction of an effective dose and patient sensitivity, thereby optimizing treatment and avoiding unnecessary administration.
Implementation Method 1
A method involving mass spectrometry to determine XMP levels in blood before and after administration of 5-hydroxy-1H-imidazole-4-carboxamide
Implementation Method 2
using specific chromatography conditions to quantify XMP
Data Source
Figure 1~2
Figure 3~4
Figure 5~6
AI summary
An object of the present invention is to provide a method and apparatus for predicting an effective dose of or the sensitivity to 5-hydroxy-1H-imidazole-4-carboxamide, which are capable of performing a determination in a simple operation and a short time, a method for determining amounts of xanthosine monophosphate, and a treatment agent and treatment method for treating myelodysplastic syndrome. According to the present invention, provided are a method for predicting an effective dose of or the sensitivity to 5-hydroxy-1H-imidazole-4-carboxamide, including determining amounts of xanthosine monophosphate in blood and a prediction apparatus, a method for determining amounts of xanthosine monophosphate, including determining xanthosine monophosphate in blood in two different determining conditions by mass spectrometry, and a treatment agent and treatment method for treating myelodysplastic syndrome.